Global Antipsychotic Drugs Market Revenue Grows at a CAGR of 6.18%

Introduction

Straits Research released its highly anticipated report, “Global Antipsychotic Drugs Market Size & Outlook, 2026-2034”. According to the study, the market size is valued at USD 17.97 billion in 2025 and is anticipated to grow to USD 30.73 billion by 2034, growing at a CAGR of 6.18% from 2026-2034.

Market Dynamics

The antipsychotic drugs market expands through rising adoption of structured mental health programs that encourage earlier diagnosis and consistent treatment initiation across diverse care settings, creating stronger demand for both established and newer therapeutic options. Growth is moderated by variable continuity of psychiatric follow-up, which leads to uneven medication adherence and limits stability of long-term treatment outcomes across regions with constrained mental health resources. The market presents an opportunity through the widening use of digital mental health platforms that support remote monitoring, virtual consultations, and personalized treatment guidance, creating new pathways for improved engagement and broader integration of antipsychotic therapies within community-based and home-based care environments.

Market Highlights

• Class: Based on Class, the Second Generation segment dominates the market with a revenue share of 66.23%.
• Disease: Based on Disease, the Schizophrenia segment dominates the market with a revenue share of 41.23%.
• Drug Outlook: Based on Drug Outlook, the Aripiprazole segment dominates the market with a revenue share of 42.35%.
• Distribution Channel: Based on the Distribution Channel, the Retail Pharmacies segment dominates the market with a revenue share of 53.45%.
• Regional Insights: North America held a dominant share of the global market, accounting for 38.24% share in 2025.

Competitive Players

1. AstraZeneca
2. Hikma Pharmaceuticals PLC
3. Otsuka Pharmaceutical Co., Ltd.
4. Johnson & Johnson
5. Eli Lilly and Company
6. AbbVie Inc.
7. Teva Pharmaceutical Industries Ltd
8. Reddy’s Laboratories Ltd.
9. Sumitomo Pharma Co., Ltd.
10. Alkermes
11. Bristol-Myers Squibb Company
12. Others

Recent Developments

April 2025: Johnson & Johnson announced that it had completed its acquisition of Intra-Cellular Therapies, Inc. Intra-Cellular Therapies became part of Johnson & Johnson and was to operate as a business unit within Johnson & Johnson Innovative Medicine.

Segmentation

1. By Class (2026-2034)
   1. First Generation
   2. Second Generation
   3. Third Generation
2. By Disease (2026-2034)
   1. Schizophrenia
   2. Bipolar Disorder
   3. Unipolar Depression
   4. Dementia
   5. Others
3. By Drug Outlook (2026-2034)
   1. Risperidone
   2. Quetiapine
   3. Olanzapine
   4. Aripiprazole
   5. Brexpiprazole
   6. Paliperidone Palmitate
   7. Others
4. By Distribution Channel (2026-2034)
   1. Hospital Pharmacies
   2. Retail Pharmacies
   3. Online Pharmacies